Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

24.3K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
24.3K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.3K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.3K
Stem Cell Culture01:17

Stem Cell Culture

5.3K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
5.3K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.1K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation.

Frontiers in immunology·2026
Same author

Generation of therapeutic T cells from human induced pluripotent stem cells.

Inflammation and regeneration·2026
Same author

IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Stress-induced CXCL13 regulates pancreatic exocrine homeostasis, age-related chronic inflammation, and cancer progression.

Science advances·2026
Same author

Emerging applications of human iPSCs in pituitary diseases.

Nature reviews. Endocrinology·2026
Same author

Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.

Endocrine journal·2026

Related Experiment Video

Updated: Jul 29, 2025

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K

[Basic Research and Clinical Development of Regenerative Immunotherapy Using iPS Cells].

Keitaro Kanie1, Shin Kaneko

  • 1Laboratory of Regenerative Immunotherapy, Dept. of Cell Growth and Differentiation, Center for iPS Cell Research and Application(CiRA), Kyoto University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 23, 2023
PubMed
Summary

Induced pluripotent stem cells offer a promising solution for cell-based immunotherapies, overcoming limitations of current treatments for hematological malignancies by enabling "off-the-shelf" cell therapies.

More Related Videos

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

18.9K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K

Related Experiment Videos

Last Updated: Jul 29, 2025

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K
Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

18.9K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K

Area of Science:

  • Regenerative medicine and immunotherapy
  • Hematological oncology

Background:

  • Current autologous cell therapies like CAR-T cells show promise for hematological malignancies but face challenges including high costs, manufacturing difficulties, and T cell exhaustion.
  • Induced pluripotent stem (iPS) cells possess unlimited proliferation and differentiation potential, offering a viable alternative to overcome current immunotherapy limitations.

Approach:

  • Reviewing the clinical development of regenerative immunotherapies utilizing iPS cell-derived immune cells.
  • Focusing on iPS cell-derived CD8 killer T cells and natural killer (NK) cells.
  • Outlining regenerative strategies involving iPS cell-derived natural killer T (NKT) cells, γδ T cells, mucosal-associated invariant T (MAIT) cells, and macrophages.

Key Points:

  • iPS cells can be genetically engineered and differentiated into various immune cell types, creating an abundant source for "off-the-shelf" cell therapies.
  • This approach addresses the limitations of autologous therapies, potentially reducing costs and improving manufacturing scalability.
  • The review covers a broad spectrum of iPS cell-derived immune effector cells for cancer immunotherapy.

Conclusions:

  • iPS cell-derived immunotherapies represent a significant advancement in regenerative medicine for treating hematological malignancies.
  • The development of "off-the-shelf" iPS cell-based therapies holds the potential to enhance accessibility and long-term efficacy compared to current autologous treatments.